NCI's Featured Clinical Trial involves patients with DLBCL

The National Cancer Institute's Featured Clinical Trial concerns patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma.

Trial Name

Phase III Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab (EPOCH-R) in Patients with Previously Untreated De Novo Diffuse Large B-Cell Non-Hodgkin Lymphoma (CALGB-50303).

Trial focus

Patients with previously untreated Diffuse large B-cell lymphoma (DLBCL) will be randomly assigned to receive either R-CHOP or EPOCH-R for 6 to 8 cycles. NCI researchers believe that there may be three different subtypes of DLBCL that have varying patterns of gene expression.

Endpoints

- "Can EPOCH-R produce better clinical outcomes than R-CHOP for patients with DLBCL?"
- "Can we use gene expression profiling to determine prognostic molecular characteristics that will tell us which patients benefit most from these different regimens?”

Additional Information

- Entry criteria
- Trial contact information
- NCI's Cancer Information Service (toll-free and confidential): 1-800-4-CANCER (1-800-422-6237).